Feature Channels: Clinical Trials

• share
• favorite_border

The road from discovering a potential drug to getting the therapy into the hands of patients is a long and uncertain one. An NIH program offers researchers a smoother path from basic science to clinical testing and regulatory approval.

• share
• favorite_border

Hackensack Meridian Hackensack University Medical Center started a new study investigating the impact of omega-3 supplements on post-COVID symptoms.

• share
• favorite_border

New data from MD Anderson-led studies on ATR inhibitor and next-generation PARP1 inhibitor presented at AACR Annual Meeting

• share
• favorite_border

New data to be presented by Grace Dy, MD, at the American Association for Cancer Research Annual Meeting show that patients with non-small cell lung cancer (NSCLC) who received the targeted therapy sotorasib experienced extended survival and good quality of life.

• share
• favorite_border

Combining a beta-blocker with the cancer immunotherapy drug pembrolizumab could be a promising new treatment option for many hard-to-treat solid-tumor cancers. Researchers from Roswell Park Comprehensive Cancer Center will report on a study of of this treatment combination in patients with advanced or metastatic melanoma at the American Association for Cancer Research (AACR) Annual Meeting 2022.

• share
• favorite_border

Two Roswell Park Comprehensive Cancer Center oncologists will discuss promising strategies for making breakthrough immunotherapies work for more patients at the annual meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana, on Monday, April 11.

• share
• favorite_border

UC San Diego has joined a Phase II clinical trial to evaluate various additional COVID-19 booster shots. The trial seeks to understand if different vaccine regimens can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.

• share
• favorite_border

Dozens of cancer specialists at Roswell Park Comprehensive Cancer Center have been invited to present their latest advances in cancer research at the annual meeting of the American Association for Cancer Research (AACR), which will take place in New Orleans, Louisiana, from April 8 to 13.

• share
• favorite_border

Here are some of the latest articles that have been added to the Clinical Trials channel on Newswise.

• share
• favorite_border

UCSF, in collaboration QLHC and the FDA, has developed the OneSource electronic data capture (EDC) system to seamlessly integrate clinical care and research by streamlining collection and distribution of patient health data for clinical trials. It is currently being deployed in the I-SPY COVID trial and expanding to I-SPY 2.2 trial for breast cancer.

• share
• favorite_border

Addressing disparities in cancer care, including access to and participation in clinical trials, has long been a priority for Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health. Sanjay Goel, MD, MS, director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute shares more.

• share
• favorite_border

A new drug shows promise in providing relief to hypertrophic cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C.

• share
• favorite_border

Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental “gene silencing” therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%. Findings from the “APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial” were presented today during a late-breaking science session at American College of Cardiology’s 71st Annual Scientific Session and simultaneously published online in the Journal of the American Medical Association.

• share
• favorite_border

Findings from a Cleveland Clinic-led clinical trial showed that the use of an experimental drug in severely symptomatic, hypertrophic cardiomyopathy patients significantly reduced the need for invasive procedures.

• share
• favorite_border

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a progressive genetic condition that causes movement challenges and cognitive decline. UC Davis MIND Institute researchers have shown, for the first time, how FXTAS can manifest in its earliest stages.

• share
• favorite_border

AU professor awarded $6.4 million grant for clinical trial researching dietary intervention in U.S. veterans suffering from Gulf War Illness

• share
• favorite_border

A comprehensive look at all of the active clinical trials on new CRISPR-based genome editing therapies in 2022, and perspective on what is coming next.

• share
• favorite_border

A study published in the Journal of the American Medical Association Surgery is the first in North America to demonstrate that living-donor liver transplant is a viable option for patients who have systemically controlled colorectal cancer and liver tumors that cannot be surgically removed.

• share
• favorite_border

Treatment for glioma has long relied on MRI imaging to track tumor markers and treatment response. But findings from a team at the University of Michigan Rogel Cancer Center, led by Carl Koschmann, M.D., pediatric neuro-oncologist at University of Michigan Health C.S. Mott Children’s Hospital and researcher with the Chad Carr Pediatric Brain Tumor Center, suggest a new method could provide additional data about tumor markers before changes appear on an MRI, indicating possible strategies to help clinicians address this aggressive form of cancer. The recent study appeared in Neuro-Oncology.

• share
• favorite_border

A team of clinical investigators at the Icahn School of Medicine at Mount Sinai has announced the launch of a Phase 1, open-label, placebo-controlled study to evaluate the safety and immunogenicity of an egg-based COVID-19 vaccine in healthy, vaccinated adults who have never been infected with COVID-19.

• share
• favorite_border

Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma (LBCL). The study was published today in Nature Medicine, and results recently were presented at the 2021 American Society of Hematology (ASH) meeting.

• share
• favorite_border

Letrozole and abemaciclib cause tumor shrinkage or stabilization in 75% of patients in phase 2 trial. Approximately 30% of trial participants had their tumors shrink by more than 30%

• share
• favorite_border

Now a couple of years after this discovery, Pete Nelson, the R.C. Durr Foundation Chair in Alzheimer's Disease at the University of Kentucky, is working towards the second part of the dream, with the world’s first clinical trial for LATE officially underway by his colleagues at UK.

• share
• favorite_border

UChicago researchers discovered several important mechanisms that affect how ovarian cancer tumors interact with the immune response and how combination therapies can exploit these pathways to improve ovarian cancer treatment.

• share
• favorite_border

The Dementia Care Study (D-CARE), a nation-wide clinical trial assessing the effectiveness of different approaches to caring for people with Alzheimer’s disease and other dementias, has reached its recruitment goal by enrolling 2,176 persons living with dementia and their caregivers

• share
• favorite_border

Mass Eye and Ear research shows the viral vector Anc80L65 efficiently transferred genetic cargo into the inner ear of nonhuman primates via a specialized surgical procedure, paving the way for a method that can be brought to clinical trials for hearing loss and vestibular disorder treatments.

• share
• favorite_border

A new clinical trial from a team at the University of Michigan Rogel Cancer Center uses innovative basic science research methods to offer hope and a new treatment to glioblastoma patients. A collaborative team of Rogel physicians, led by Daniel Wahl, M.D., Ph.D., hopes that grounding their trial in rigorous and innovative biology from the very beginning will help this approach succeed where so many other potential glioblastoma treatments have failed.

• share
• favorite_border

In a first of its kind clinical trial led by UC Davis Health, HOPE-2 showed that cellular therapy is safe and effective in stopping the deterioration of upper limb and heart functions in patients with late-stage Duchenne muscular dystrophy.

• share
• favorite_border

Adding the proteasome inhibitor bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL), according to a Children’s Oncology Group (COG) study led by researchers at Children’s Hospital of Philadelphia (CHOP). This international phase 3 clinical trial also found that radiation could be eliminated in 90% of children with T-cell acute lymphoblastic leukemia (T-ALL) when the chemotherapy regimen was intensified.

• share
• favorite_border

Malignant Pleural Mesothelioma (MPM) is an aggressive cancer mostly related to asbestos exposure whose incidence is constantly rising, especially in low-income countries.

• share
• favorite_border

Don't miss these articles in our Staff Picks channel

• share
• favorite_border

University of Utah Health researchers are leading a five-year, $22-million nationwide clinical trial for NMDA receptor encephalitis––a type of autoimmune encephalitis that prompts the immune system to mistakenly attack the brain, causing confusion, memory loss, seizures, and symptoms similar to bipolar disorder and other psychiatric conditions.

• share
• favorite_border

Announcement of contents of the March 2022 issue of Neurosurgical Focus: Video

• share
• favorite_border

Investigators in Female Pelvic Medicine at Hackensack Meridian Hackensack University Medical Center Department of Urology have completed two studies and are conducting a third aimed at improving the standard of care for common urologic disorders in women.

• share
• favorite_border

The ACR is launching new initiatives to reduce racial disparities in lupus clinical trials: Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY) and new Continuing Medical Education (CME) for dermatologists and nephrologists.

• share
• favorite_border

African Americans have an increased risk of kidney failure, and new research shows that some of this risk is related to variations in a gene called apolipoprotein L1 (APOL1). Scientists will address racial disparities in kidney transplant outcomes.

• share
• favorite_border

Prominent gynecologic oncologist and surgeon B.J. Rimel, MD, recently was named medical director of the Cedars-Sinai Cancer Clinical Trials Office. She will serve as a medical liaison between clinical trial principal investigators and Cedars-Sinai Cancer leadership to ensure the quality of services provided to patients.

• share
• favorite_border

UC San Diego School of Medicine, Weill Cornell Medicine and Stanford Medicine have launched a three-year study to investigate new ways to treat or prevent major depression, accelerate effective treatments and develop predictive models to identify which treatments work best for individual patients.

• share
• favorite_border

Over 90 percent of patients with transfusion-dependent thalassemia, an inherited blood disorder, no longer needed monthly blood transfusions years after receiving gene therapy, according to an international Phase 3 clinical trial that for the first time included children younger than 12 years of age. Twenty-two patients were evaluated (ranging in age 4-34 years), including pediatric patients enrolled at Ann & Robert H. Lurie Children’s Hospital of Chicago.

• share
• favorite_border

Experts at Overlook are hoping that SurVaxM, a first-of-its-kind vaccine targeting a protein found in glioblastomas and other cancers, will give patients a better shot at long-term survival and improved function.

• share
• favorite_border

The Latest Research News in Cardiovascular Health

• share
• favorite_border

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University has expanded its testing platform to evaluate ivermectin at a higher dose for a longer period of time.

• share
• favorite_border

Ivermectin is not approved by the FDA to treat or prevent COVID-19. Nonetheless, prescriptions of ivermectin by U.S. health care providers increased more than tenfold from 3,589 per week pre-COVID-19 to 39,102. In addition, the NIH, WHO and European Medicine Agency have all advised against using ivermectin to treat or prevent COVID-19. Researchers urge all health care providers to always prioritize compassion with reliable evidence on efficacy and safety. As such, they recommend a moratorium on prescribing ivermectin to treat or prevent COVID-19, except to provide the necessary evidence in data from large-scale randomized trials.